ArticleJournal of healthcare risk management : the journal of the American Society for Healthcare Risk Management2026
Proactive risk assessment and nursing risk management in chemotherapy drugs: FMECA methodology results.
Article in Journal of healthcare risk management : the journal of the American Society for Healthcare Risk Management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proactive risk assessment and nursing risk management in chemotherapy drugs: FMECA methodology results.Journal of healthcare risk management : the journal of the American Society for Healthcare Risk Management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aims to proactively analyze the chemotherapy drug management process, focusing on the nursing role: identifying error modes and proposing improvement interventions. A quality improvement project was conducted at an Onco-Hematological Department, applying a systematic and prospective approach to evaluate the critical phases of the chemotherapy drug process. A risk analysis was conducted using Failure Mode, Effects, and Criticality Analysis (FMECA). A multidisciplinary team of healthcare professionals with experience in the sector mapped the process, identified potential failure modes, calculated the Risk Priority Numbers (RPNs), and implemented corrective actions. The RPNs were re-evaluated after three months to measure intervention effectiveness. The analysis identified eight error modes, two of which were classified as high risk: contamination (initial RPN 27) and inaccurate dosing (initial RPN 24). After the implementation of improvement actions, such as specific training and formalized double checking, the RPNs were reduced to 4 and 3, respectively, with an improvement greater than 85%. The application of FMECA has allowed for effective identification and mitigation of the main risks associated with chemotherapeutic drug management, contributing to improve patient safety and nurse perceived quality of performance, through a model replicable in other healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.